Takeda takes tardy Edarbi to Germany first after EU approval
This article was originally published in Scrip
Executive Summary
Takeda's late-coming angiotensin II receptor blocker (ARB) Edarbi (azilsartan medoxomil) has received EU approval for use in essential hypertension following a CHMP positive opinion in September.